Gruppo Lepetit

The Dow Chemical Company

Vicuron Pharmaceuticals Inc.

Biosearch Italia S.p.a.

Francesco Parenti

Enrico Selva

Giovanni Cassani

Carolina Coronelli

Giorgio Tamoni

Maurizio Denaro

Beth P Goldstein

Hermes Pagani

Ernesto Riva

Grazia Beretta

Giancarlo Lancini

Luciano Gastaldo

Vittorio Arioli

Romeo Ciabatti

Angelo Borghi

Pietro Ferrari

Gianpaolo Candiani

Marco Cavaleri

Maria Rosa Bardone

Luigi Simioni

Richard White

Giorgion Tamoni

The present invention relates to a pharmaceutical composition for intravenous administration that contains ramoplanin or a member of the ramoplanin family.

Injectable formulations containing ramoplanin

The present invention is directed to a method for selectively enhancing the production of factors A, and/or B.sub.0 of antibiotic A 40926 either to isolate these single components in better yields or to enrich the complex in one or both the above components, which comprises adding an appropriate precursor of the desired antibiotic factor to an A 40926 producing culture during fermentation.

Method for selectively enhancing the production of factors A or B.sub.0

Use of the antibiotic purpuromycin for the topical treatment of infectious vaginitis and topical dosage forms containing said product. The antibiotic purpuromycin is simultaneously active against the main causative agents of infectious vaginitis i.e.: Candida vaginalis, Trichomonas vaginalis and Gardnerella vaginalis.

Purpuromycin for the treatment of vaginal infections and pharmaceutical

A novel antibiotic, A 42867, is prepared by cultivating the strain Nocardia sp. ATCC 53492, or an antibiotic A 42867-producing mutant or variant thereof, under submerged aerobic conditions in the presence of assimilable sources of carbon, nitrogen and inorganic salts. The antibiotic and its addition salts are useful in the treatment of infectious diseases and as growth promotant agents.

Nocardia sp. ATCC 53492, or an antibiotic A 42867 producing mutant or

The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Antibiotic A 40926 complex and its pure factors PA, PB, A, B and B.sub.0

The present invention concerns new antibiotic substances denominated antibiotic A 40926 N-acylaminoglucuronyl aglycon complex AB, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor A, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.0, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.1, antibiotic A 40926 aglycon and the addition salts thereof, a process for their preparation starting from antibiotic A 40926 complex or a factor thereof, and their use in the treatment of infectious diseases involving microorganisms susceptible to them.

Antibiotic A 40926 N-acylaminoglucuronyl aglycons and antiobiotic A

Antibiotic A 42867 and the addition salts thereof

The present invention concerns a new antibiotic substance denominated antibiotic A 40926 mannosyl aglycon and the addition salts thereof, a process for preparing it from antibiotic A 40926 complex or a factor thereof, and its use in the treatment of infectious disease involving microorganisms susceptible to it.

Antibiotic A 40926 mannosyl aglycon

The present invention concerns a new antibiotic substance arbitrarily designated as antibiotic SB 22484, to a process for its production by culturing Streptomyces sp. NRRL 15496 or a producing variant or mutant thereof, and to the use of the new antibiotic substance in the treatment of infectious diseases involving microorganisms susceptible to this antibiotic substance.

Antibiotic SB 22484

A biologically pure culture of Actinoplanes sarveparensis.

Biologically pure culture

The antibiotic gardimycin and process for producing said antibiotic by fermentation of strains belonging to the genus Actinoplanes.

Antibiotic substances

This invention relates to a novel antibiotic mixture and to the process for its production. This antibiotic mixture comprises a family of new antibiotic substances which may be separated and isolated as individual components. These antibiotic substances are referred to herein as antibiotic 8327 factor A, antibiotic 8327 factor B and antibiotic 8327 factor C. Antibiotic 8327 factor A is in turn a mixture of three fractions which will be referred to herein as teichomycin A.sub.1, teichomycin A.sub.2 and teichomycin A.sub.3. The novel antibiotic mixture is obtained by cultivation of strain Actinoplanes teichomyceticus nov. sp. ATCC 31121.

A new antibiotic prepared from aerobic cultivation of Actinoplanes sarveparensis and a method for producing the same from a culture medium.

Antibiotic substance from Actinoplanes sarveparensis CBS 305.76

Gardimycin and process for producing same

The novel antibiotic, lipiarmycin, is prepared by cultivating Actinoplanes deccanensis A/10655, ATCC 21983, under aerobic conditions in a fermentation broth, from which it is then recovered.

Growing community of inventors

Lainate, Italy

Francesco Parenti